Actively Recruiting
Phase 3 Study of AK112 Plus Nab-Paclitaxel Compared to Placebo Plus Nab-Paclitaxel as First Treatment for Inoperable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Led by Akeso · Updated on 2026-03-16
416
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of AK112 combined with Nab-Paclitaxel compared to a placebo plus Nab-Paclitaxel as a first treatment for people with inoperable locally advanced or metastatic triple-negative breast cancer TNBC. This randomized, double-blind, multicenter Phase III study aims to provide new information on treating this aggressive breast cancer type. Participants receive either AK112 plus Nab-Paclitaxel or a placebo plus Nab-Paclitaxel. Nab-Paclitaxel is given by intravenous infusion at 100 mgm2 on Days 1, 8, and 15 of each 28-day cycle. AK112 and placebo are also administered by intravenous infusion. Study treatment continues as per the assigned group to compare outcomes. Throughout the study, participants will have regular assessments including tumor evaluations by imaging using RECIST v1.1 criteria. Safety will be monitored by tracking adverse events and laboratory tests. Researchers will measure progression-free survival and overall survival up to about 2 and 4 years respectively. Additional measures include response rates, duration of response, and immune-related markers. The study is expected to last until December 2028, with participants followed closely during treatment and after.
CONDITIONS
Brief Title
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Research Team
X
Xufang Yu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here